PTN Palatin Technologies, Inc. Comm

0.40
+0.01  (2.56%)
Previous Close 0.39
Open 0.42
Price To book 0.00
Market Cap 53.37M
Shares 133,423,000
Volume 2,319,850
Short Ratio 2.24
Av. Daily Volume 2,752,690

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due early 2018.
Rekynda
Female sexual dysfunction (FSD)
Phase 2 planned for 1H 2017
PL-3994
Heart failure

Latest News

  1. PALATIN TECHNOLOGIES INC Financials
  2. PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report
  3. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition
  4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2017 Results; Teleconference and Webcast to be held on February 9, 2017
  5. Q2 2017 Palatin Technologies Inc Earnings Release - Before Market Open
  6. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  7. Palatin Technologies Announces Closing of License Agreement with AMAG Pharmaceuticals for North American Rights to Rekynda™
  8. Palatin (PTN) Sees Hammer Chart Pattern: Time to Buy?
  9. Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™
  10. AMAG Pharmaceuticals, Inc. (AMAG), Palatin Technologies, Inc. (PTN) In Licensing Deal
  11. AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder
  12. Why AMAG Pharmaceuticals, Inc. Is Falling Today
  13. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  14. AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekyndatm (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
  15. AMAG Pharmaceuticals and Palatin Technologies Enter Into Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide), a Potential Treatment for a Common Female Sexual Disorder
  16. How CytRx Corporation (CYTR) Stacks Up Against Its Peers
  17. Palatin Technologies Closes on $16.5 Million Financing
  18. PALATIN TECHNOLOGIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement
  19. Palatin Technologies Announces Proposed Public Offering of Common Stock and Warrants
  20. Palatin Technologies Announces Pricing of Public Offering of Common Stock and Warrants

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17602637
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17593538
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17587846
  4. 8-K - Current report 17584693
  5. 8-K - Current report 17570367
  6. 8-K - Current report 17515868
  7. 424B5 - Prospectus [Rule 424(b)(5)] 162029414
  8. 8-K - Current report 162029082
  9. 424B5 - Prospectus [Rule 424(b)(5)] 162025472
  10. S-8 - Securities to be offered to employees in employee benefit plans 161999861